Alternative vaccine delivery methods

Weniger, Bruce G.; Papania, Mark J.

doi:10.1016/b978-1-4557-0090-5.00063-x

Cited by 63 publications

(45 citation statements)

References 756 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an alternate vaccine delivery system, inhalation of MVDP offers many potential advantages including needle free delivery, lower skill level required for vaccinators and potential cost reduction. The benefits of needle free vaccination are widely recognized and have provided motivation for this work [7,30]. An economic model of the potential cost effects of alternate vaccine delivery systems indicated that dry powder vaccination provided the most cost advantage of the systems studied.…”

Section: Discussionmentioning

confidence: 99%

“…Puffhaler ® (manufactured by AktivDry LLC) is an experimental dry powder inhaler designed to aerosolize powders into a reservoir from which the powders are either directly inhaled through a mouthpiece with adults and adolescents or through a mask placed over the nose and mouth with infants and young children [7]. Powders are stored in unit-dose blister packs, placed in a plastic disperser, opened by removing the pull-tab lid, and aerosolized by squeezing a bulb attached to the disperser.…”

Section: Vaccines and Devicesmentioning

confidence: 99%

“…Solovent TM (manufactured by Becton, Dickinson & Company) is an experimental dry powder inhaler designed to aerosolize powders into a spacer from which the powders are either directly inhaled from the spacer with adults and adolescents or through a mask placed over the nose and mouth with infants and young children [7]. Powders are contained between two burstable plastic membranes in a plastic housing which is stored in a foil package to protect the vaccine from light and humidity.…”

Section: Vaccines and Devicesmentioning

confidence: 99%

“…Respiratory delivery of vaccines has typically focused on two separate target tissue areas, the nasal airways or the lower airways. The only licensed vaccines for respiratory delivery have been nasal influenza vaccines, which are delivered directly to the nares as large particle sprays to avoid deposition in the lower airways [7]. In contrast, most of the research on respiratory delivery of measles vaccine has focused on generating small particle aerosols for deposition in the lower airway [8].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial

Agarkhedkar

Kulkarni

Winston

et al. 2014

Vaccine

View full text Add to dashboard Cite

a b s t r a c tBackground: Measles is a highly infectious respiratory disease which causes 122,000 deaths annually. Although measles vaccine is extremely safe and effective, vaccine coverage could be improved by a vaccine that is more easily administered and transported. We developed an inhalable dry powder measles vaccine (MVDP) and two delivery devices, and demonstrated safety, immunogenicity, and efficacy of the vaccine in preclinical studies. Here we report the first clinical trial of MVDP delivered by inhalation. Methodology: Sixty adult males aged 18 to 45 years, seropositive for measles antibody, were enrolled in this controlled Phase I clinical study. Subjects were randomly assigned in 1:1:1 ratio to receive either MVDP by Puffhaler ® or by Solovent TM devices or the licensed subcutaneous measles vaccine. Adverse events (AEs) were recorded with diary cards until day 28 post-vaccination and subjects were followed for 180 days post-vaccination to assess potential serious long term adverse events. Measles antibody was measured 7 days before vaccination and at days 21 and 77 after vaccination by ELISA and a plaque reduction neutralization test. Results: All subjects completed the study according to protocol. Most subjects had high levels of baseline measles antibody. No adverse events were reported. MVDP produced serologic responses similar to subcutaneous vaccination. Conclusions: MVDP was well tolerated in all subjects. Most subjects had high baseline measles antibody titer which limited ability to measure the serologic responses, and may have limited the adverse events following vaccination. Additional studies in subjects without pre-existing measles antibody are needed to further elucidate the safety and immunogenicity of MVDP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Vaccines and Devicesmentioning

confidence: 99%

Section: Vaccines and Devicesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial

Agarkhedkar

Kulkarni

Winston

et al. 2014

Vaccine

View full text Add to dashboard Cite

show abstract

“…People with needle phobia, estimated at 3.5-10% of the population, 16 as well as children could also profit from the availability of such ID-devices because of increased vaccine acceptance. 2,3,[5][6][7]10,14,17,18 However, currently few devices allowing vaccination via the ID route are commercially available (e.g. Soluvia TM , MicronJet TM or needle-free injection systems), while some prototypes are in development (e.g., vaccine patch, coated, dissolving or solid microneedles).…”

Section: Introductionmentioning

confidence: 99%

Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects

Mulder

Verwulgen

Beyers

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Needle‐Free Injection Assisted Drug Delivery—Histological Characterization of Cutaneous Deposition

2019

View full text Add to dashboard Cite

Background and Objectives: Many cutaneous drugdelivery techniques rely on passive diffusion to deliver topical compounds to the skin. When attempting to deliver drugs to thicker lesions, such as skin tumors, modalities that do not rely on diffusion may serve as a better drug-delivery method. In this histological study, we aim to investigate the cutaneous delivery patterns of an electronic pneumatic needle-free injection device. Study Design/Materials and Methods: Needle-freeinjection was investigated in 24 ex vivo porcine skin samples and one basal cell carcinoma (BCC) tissue sample. A needle-free injection device with a nozzle size of 200 μm delivered 80 μl compound ink (0.1 cc black ink: 5.0 cc saline) at low (30%/3.1 bar; n = 6 porcine skin; n = 1 BCC tissue), medium (50%/3.9 bar; n = 6 porcine skin), high (65%/4.6 bar; n = 6 porcine skin), and stacked (30 + 50%/3.1 + 3.9 bar; n = 6 porcine skin) pressures. Depth, width, and depth of maximum width of ink deposition were evaluated on histological slides. Results: Depositions with small ink-lined vacuoles were seen intra-dermally in all samples, including the BCC tissue. Deposition depth was similar at low and medium pressures (924 vs. 994 μm; P = 0.873) but increased significantly with high pressure (1,564 μm; P = 0.010). When injections were stacked (3.1 + 3.9 bar), the depth remained similar to that of a single injection (931 μm; P = 1.000). The width of the deposition stayed comparable for low, medium, and high pressures when a single needlefree injection was performed (30% = 2,394 μm; 50% = 2,226 μm; and 65% = 2,757 μm; P = 0.09), but increased significantly with stacking (2,979 μm; P = 0.037). The depth of maximal width was superficially located in the papillary dermis at low and medium pressures (321 and 305 μm; P = 0.748) but shifted to the deeper reticular dermis with high pressure (950 μm; P = 0.004) and with stacking (734 μm; P = 0.004). Conclusions: In conclusion, with an electronically controlled, pneumatic needle-free injector, depth and width of a cutaneous deposition can be influenced by pressure and stacking, respectively. The pneumatic needle-free injection can potentially serve as a viable drug-delivery technique for cutaneous pathologies where dermal deposition is essential. Lasers Surg. Med.

show abstract

Alternative vaccine delivery methods

Cited by 63 publications

References 756 publications

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial

Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects

Needle‐Free Injection Assisted Drug Delivery—Histological Characterization of Cutaneous Deposition

Contact Info

Product

Resources

About